Amy Schulman

Insider profile

Currently holds positions in SQZ Biotechnologies Co and Alnylam Pharmaceuticals Inc

Performance

Overall performance
2.6
Performance over holding periods
2.6
30 days 90 days 120 days
Average return 20% 8.2% 15.1%
Success rate 28% 68% 82%
Transactions
8 88% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Executive Chairman SQZ Biotechnologies Co None -
Independent Director Alnylam Pharmaceuticals Inc July 1, 2014 -
Independent Director Ironwood Pharmaceuticals, Inc. Jan. 1, 2017 - April 1, 2019
Lead Independent Director X4 Pharmaceuticals Inc Feb. 1, 2015 - March 13, 2019
Independent Director Blue Buffalo Pet Products Inc Jan. 1, 2014 - April 24, 2018
Executive Vice President, General Counsel, Business Unit Lead - Consumer Healthcare Pfizer Inc Aug. 1, 2012 - Dec. 17, 2013
Director Zoetis Inc July 1, 2012 - June 24, 2013
Executive Vice President, General Counsel, President and General Manager - Nutrition Pfizer Inc Dec. 1, 2010 - Aug. 1, 2012
Amy Schulman's trades of Elevance Health Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Sale
Price
446.33
Quantity 60,545 -4.3%
Value US$3,412,637
Transaction date
Purchase
Price
150.32
Quantity 53,020 +49.5%
Value US$3,903,855
Transaction date
Proposed sale
Price
240.00
Quantity 8,500
Value US$2,040,000
Transaction date
Proposed sale
Price
149.76
Quantity 21,700
Value US$3,249,792
Transaction date
Purchase
Price
10.94
Quantity 1,850 New position
Value US$20,239
Transaction date
Purchase
Price
10.88
Quantity 1,850 New position
Value US$20,128
Transaction date
Purchase
Price
16.00
Quantity 233,654 +10.1%
Value US$3,738,464
Transaction date
Purchase
Price
16.00
Quantity 16,346 +10.1%
Value US$261,536
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-23 2026-03-12
S Sale
60,545 -4.3%
446.33
US$3,412,637 		60,545 -4.3% 446.33 US$3,412,637
2025-03-17 2025-03-13
B Purchase
53,020 +49.5%
150.32
US$3,903,855 		53,020 +49.5% 150.32 US$3,903,855
2024-06-27 2024-06-25
PlS Planned sale
63,003 -10.9%
445.59
US$1,582,985 		63,003 -10.9% 445.59 US$1,582,985
2024-06-25 2024-06-25
PrS Proposed sale
8,500
240.00
US$2,040,000 		8,500 240.00 US$2,040,000
2024-05-31 2024-05-29
PlS Planned sale
63 -0.7%
149.76
US$9,435 		63 -0.7% 149.76 US$9,435
2024-05-31 2024-05-29
PlS Planned sale
11,516 -57.5%
148.93
US$1,715,078 		11,516 -57.5% 148.93 US$1,715,078
2024-05-31 2024-05-29
PlS Planned sale
10,121 -33.6%
148.21
US$1,500,033 		10,121 -33.6% 148.21 US$1,500,033
2024-05-29 2024-05-29
PrS Proposed sale
21,700
149.76
US$3,249,792 		21,700 149.76 US$3,249,792
2021-12-15 2021-12-13
B Purchase
1,850 New position
10.94
US$20,239 		1,850 New position 10.94 US$20,239
2021-12-15 2021-12-13
B Purchase
1,850 New position
10.88
US$20,128 		1,850 New position 10.88 US$20,128
2020-11-03 2020-11-03
B Purchase
233,654 +10.1%
16.00
US$3,738,464 		233,654 +10.1% 16.00 US$3,738,464
2020-11-03 2020-11-03
B Purchase
16,346 +10.1%
16.00
US$261,536 		16,346 +10.1% 16.00 US$261,536
2019-04-10 2019-04-08
B Purchase
21,635 New position
16.00
US$346,160 		21,635 New position 16.00 US$346,160
2019-04-10 2019-04-08
B Purchase
604,482 New position
16.00
US$9,671,712 		604,482 New position 16.00 US$9,671,712